A new HPLC method for the determination of Metronidazole was established. The determination was performed by using a Kinetex C18 analytical column with a gradient mobile phase system consisting of 0.05M KH₂PO 4 (pH 3.5), pH adjusted with ortho phosphoric acid (mobile phase A) and Acetonitrile (mobile phase B). The flow rate was 1ml/min. and quantitation was achieved with UV detection at 230 nm, based on peak area. The retention time obtained was 5.35 ± 0.004 and the method was validated according to ICH guidelines regarding linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, robustness, and selectivity. Excellent linearity was observed for the calibration curve with an excellent correlation coefficient 0.9999. Limit of detection was 0.78 μg mL−1; limit of quantitation 2.37 μg mL−1. The developed method was found to be accurate and sensitive and is ideally suited for analysis of MTZ in pure form, pharmaceutical dosage form and spiked urine samples.
Introduction:
Metronidazole (MTZ) is (2-Methyl-5-nitro-1H-imidazol-1-yl) ethanol, a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities. It inhibits nucleic acid synthesis by disrupting the DNA of microbial cells (Metla 2015) . This function only occurs when metronidazole is partially reduced, and because this reduction usually happens only in anaerobic cells, it has relatively little effect upon human cells or aerobic bacteria (Schaechter, Engleberg et al. 2012) . Reduced metronidazole causes DNA strand breaks, thereby inhibiting DNA synthesis and bacterial cell growth. It is still the drug of choice for treatment of anaerobic infections and considered to be a cost-effective drug because of its low cost, good activity against pathogenic anaerobic bacteria, favorable pharmacokinetic and pharmacodynamic properties, and minor adverse effects (Löfmark, Edlund et al. 2010) . Different analytical methods were proposed for analysis of MTZ in pure form, different pharmaceutical preparations and biological fluids, including, Spectrophotometric methods (Nagaraja, Sunitha et al. 2002 , Saffaj, Charrouf et al. 2004 , Saffaj, Charrouf et al. 2006 , HPLC methods (Akay, Özkan et al. 2003 , Tavakoli, Varshosaz et al. 2007 , Suyagh, Iheagwaram et al. 2010 , electrochemical methods (Lű, Wu et al. 2004 , Bartlett, Ghoneim et al. 2005 , Peng, Hou et al. 2012 , capillary electrophoresis methods (Jin, Li et al. 2000) and HPTLC method (Meshram, Bagade et al. 2009 ). So the aim of this work is the determination of MTZ mainly in human urine and also in pharmaceutical dosage forms and pure form. 
Materials & reagents
All reagents used during the study were of HPLC grade. MTZ was kindly provided by Egyptian int. pharmaceutical industry Co. (E.I.P.I.Co) 10 th of Ramadan city, industrial area B1, Egypt and certified to contain 99.6%. Potassium dihydrogen phosphate and phosphoric acid were purchased from El Nasr chemical Co., (Abo Zaabal ,Cairo, Egypt). Water, methanol, and acetonitrile HPLC grade were purchased from Merk. All solutions used during the process were filtrated through Whatman polytetrafluoroethylene (PTFE) membrane filter 0.2μm that was purchased from Sigma Aldrich. All sample solutions were filtered through Whatman (PTFE) 0.2μm syringe filter, was purchased from Sigma Aldrich. 0.05M of KH 2 PO 4 was prepared by dissolving the calculated amount from KH₂PO 4 in one liter HPLC water then the pH was adjusted to 3.5 with ortho phosphoric acid.
Pharmaceutical dosage form
Flagyl® tablets, were labeled to contain 500mg MTZ per tablet (Batch No. 7EG013), manufactured by Sanofi Egypt.
Preparation of standard drug solutions

Stock solutions
Stock standard solution (100 μg ml‾¹) was prepared by transferring accurately weighted 10 mg of MTZ into 100ml volumetric flask, diluted with about 70 ml methanol and sonicated for 10 min then the flask was diluted to 100 ml with methanol to obtain stock solution (100 μg ml‾¹), and stored in refrigerator at 4C˚ Each prepared stock solution was further diluted immediately before use, to obtain a working solution within the concentration range.
Urine samples
Different volumes of MTZ stock standard solution were transferred to 10 ml volumetric flasks, 1ml blank urine was added. Acetonitrile was used as protein precipitating agent to remove any proteinous material. The solutions were diluted to 10 ml with mobile phase to obtain concentration range from 5 to 75 μg ml -1 of MTZ.
Chromatographic conditions
HPLC analysis was performed according to the following conditions;
The HPLC separation and quantitation were made on a 100 x 4.6 mm (i.d.) Kinetex C18 (2.6 µm particle size) analytical column. The mobile phase was 0.05M KH₂PO 4 (pH 3.5) (mobile phase A) and Acetonitrile (mobile phase B). The gradient program consisted of 0-5 min 80% mobile phase A; 5-10 min gradient up to 50 mobile phase . fter 10 min the gradient was returned to the initial condition and the analytical column was reconditioned for 10 min. The flow rate was 1 ml min-1. ll determinations were performed at 25 C temperature. The injection volume was 10 μl. The detector was set at 230 nm. The calibration curves were obtained by plotting each drug concentration against the corresponding peak area.
Procedure for pharmaceutical dosage forms
Ten tablets of Flagyl® 500 mg were finally powdered and mixed thoroughly. An accurate amount equivalent to 10 mg MTZ was weighted and transferred to a100 ml volumetric flask, dissolved in about 70 ml of the mobile phase, the flask content was swirled well, sonicated for 10 min, and completed to 100ml with mobile phase. The flask content was mixed well and filtrated through Whatman (PTFE) membrane filter 0.2μm, the first portion of the filtrate was rejected. The obtained stock solutions were further diluted with the mobile phase to obtain final solutions within the concentration range of the calibration.
Results and discussion
The method aims to develop, simple, sensitive, rapid, HPLC method for determination of MTZ in pure & pharmaceutical dosage forms and also spiked urine.
Chromatographic conditions
The drug separation is obtained using mobile phase consists of 0.05 M KH 2 PO 4 (pH 3.5) and acetonitrile in the described ratio, a Kinetex 2.6 C18 column 100A (4.6-mm×10-mm) as stationary phase, and flow rate of 1ml/min. The separation of the studied drug at these conditions gives optimum retention time, peak area; the retention time was 5.35 ± 0.004.
Optimization of variables
Different experimental parameters affecting the separation and the peak area of the studied drug were studied and optimized. The studied factors were the composition of mobile phase, the buffer pH, and buffer concentration each of this factors were changed individually while the others remain unchanged.
Validation of the proposed analytical method
The proposed analytical method was validated according to ICH guidelines (Guideline 2005) regarding linearity, limit of detection (LOD), limit of quantification (LOQ), precision, accuracy, robustness, and selectivity.
Linearity and range
The linearity of the proposed HPLC method was evaluated by analyzing a series of standard solution of MTZ with different concentrations ranges from 5μg ml -1 to 75μg ml -1 , under the optimum experimental conditions mentioned above, the calibration curve of the studied drug was obtained by plotting value the concentration of the drug against each corresponding peak area, each concentration was repeated three times. Statistical treatment of the data was carried out by using linear regression analysis and different analytical parameters were calculated Table 1. The correlation coefficient (r) was 0.9999 which indicates excellent linearity.
Limit of detection (LOD) and limit of quantitation (LOQ)
According to International Conference on Harmonization (ICH) recommendations (ICH 2005) , LOD and LOQ were determined. The LOQ and LOD were based on standard deviation of response, and slope of calibration curve using the equations; LOD= 3.3σ/Ѕ and LOQ= 10 σ/Ѕ, where. σ is standard deviation of intercept, Ѕ is the slope of calibration curve, the obtained results were summarized in Table 3 . The limit of detection was 0.78 μgml‾¹ and limit of quantitation was 0.83 μgml‾¹. This indicates a high sensitivity of the proposed HPLC analytical method when compared with other reported analytical methods 
Accuracy and precision
The accuracy of the proposed analytical method was evaluated at five concentrations level within the specific range of the studied drug. Each concentration was replicated three times. The mean of the three measurements was calculated as found. The results of the three measurements were represented as percent of recovery ± standard deviation, (table 2). The obtained results were in close agreement with the true values, which indicates a high accuracy of the proposed method.
In order to evaluate the precision of the proposed analytical method, both intra-day precision and interday precision were evaluated. The intra-day precision was evaluated by replicate analysis of three concentrations of the studied drug on three successive times. The inter-day precision was also evaluated by replicate analysis of 3 concentrations over a period of three successive days. Both results of intra-day and inter-day precision were summarized in Table 3 . The calculated relative standard deviation of different measurements was below 2% which indicates the excellent precision of the proposed HPLC analytical method at both levels of repeatability and intermediate precision. 
Selectivity
High selectivity of the method was approved by preparing MTZ in blank urine in concentrations within the linearity range. The laboratory prepared mixture was analyzed according to the previous procedure described under the proposed HPLC method. Satisfactory results were obtained in Table 4 , indicating the high selectivity of the proposed methods for determination of MTZ in the presence of urine matrix.
Robustness
To examine the robustness of the proposed HPLC method one experimental variable was changed individually while the other variables remain constant. The studied variables were pH of buffer solution, the composition of the mobile phase and concentration of buffer solution. To test the effect of buffer pH, the pH varies from 3.3 to 3.7, to test Table 5 indicating that small variations in any of these variables did not significantly affect the results of the suggested method. 
Analytical solutions stability
In anticipation of unexpected delays during analysis it is important to have information about the stability of all solutions. When the stability of MTZ in the mobile phase was tested, it was found that samples were stable for at least for 12 hours when kept at room temperature, protected from light, and for 2 days when stored refrigerated at 5ºC as it exhibited no chromatographic or absorbance changes. The stability of spiked Urine during storage for 2 weeks at -20ºC was also evaluated; no significant change was observed.
Application to pharmaceutical dosage form
The proposed method was successively applied for the determination of the studied drug in its pharmaceutical dosage form (Flagyl® tablet). The interference of the tablet excipients was observed in order to determine the selectivity of the proposed HPLC method. The results obtained were summarized in Table 6 . From the table, it was shown that there is no significant difference between results obtained from the proposed method and from reported method as indicated by student's ttest and F-test, as the calculated value did not exceed the theoretical value at 95% confidence level. This indicates a high accuracy of the proposed method.
Conclusion:
This work provides a new analytical method for the determination of MTZ in pure form, pharmaceutical dosage form and spiked urine.
The method has the advantages of being rapid, sensitive, selective and relatively low cost so can be used for routine analysis in quality control.
